General MedicationsORALStandard
IDELALISIB
IDELALISIB
Standard Dose
150MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview IDELALISIB is listed in Drugs@FDA under application 216921 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient IDELALISIB Form and strength TABLET;ORAL - 150MG Sponsor NATCO Submission history Latest submission status date: 2026-02-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview IDELALISIB is listed in Drugs@FDA under application 216921 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient IDELALISIB Form and strength TABLET;ORAL - 150MG Sponsor NATCO Submission history Latest submission status date: 2026-02-17 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.